Form 4: VolitionRx CFO Awarded Restricted Stock Units in Lieu of Cash Compensation

VolitionRx Ltd.'s Chief Financial Officer, Terig Hughes, was awarded 17,406 restricted stock units on June 1, 2025, as part of the company's 2015 Stock Incentive Plan.

Summary

• Terig Hughes, Chief Financial Officer of VolitionRx Ltd. (VNRX), was awarded 17,406 restricted stock units (RSUs) on June 1, 2025.
• The award was made under the Issuer's 2015 Stock Incentive Plan and was granted in lieu of cash compensation that would otherwise have been owed to Mr. Hughes.
• The RSUs are scheduled to partially vest in three equal installments of 5,802 units on June 1, 2025, July 1, 2025, and August 1, 2025, respectively.
• The award is also subject to further time-based vesting in a single installment on August 1, 2025, and generally requires continued service throughout each applicable vesting date.
• Upon vesting and settlement, Mr. Hughes will receive a number of shares of common stock equal to the number of RSUs that have vested.
• Following this reported transaction, Mr. Hughes beneficially owns 407,627 shares of common stock directly.

Sentiment

Score: 7

Explanation: The award of RSUs to a key executive aligns their interests with shareholders and can conserve company cash, which is generally positive. This is a routine compensation event and does not indicate significant operational changes.

Positives

• The award of restricted stock units aligns the Chief Financial Officer's interests with those of shareholders by increasing his equity ownership in the company.
• Granting RSUs in lieu of cash compensation can help conserve the company's cash reserves, potentially improving liquidity.

Negatives

• The future issuance of shares upon RSU vesting will result in minor dilution for existing shareholders.

Risks

• The vesting of the restricted stock units is contingent upon Terig Hughes' continued service to the company through each applicable vesting date.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential minor dilution from future share issuance upon vesting, but also increased alignment of the CFO's interests with shareholder value.
• Employees: No direct impact mentioned for other employees.

Next Steps

• Vesting of 5,802 RSUs on July 1, 2025.
• Final vesting of 5,802 RSUs and further time-based vesting on August 1, 2025.

Key Dates

Recommendation

Keywords

VolitionRx, VNRX, SEC Form 4, Restricted Stock Units, RSUs, Stock Incentive Plan, Executive Compensation, Insider Trading, CFO, Equity Award